keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy vomiting

keyword
https://www.readbyqxmd.com/read/28938598/proton-pump-inhibitors-increase-the-chemosensitivity-of-patients-with-advanced-colorectal-cancer
#1
Xiaoyu Wang, Chun Liu, Jiaqi Wang, Yue Fan, Zhenghua Wang, Yuanyuan Wang
Changes in pH can alter the uptake of chemotherapy drugs. Proton pump inhibitors (PPIs) may therefore increase the chemosensitivity of cancer cells and cytotoxicity of chemotherapeutic drugs by increasing their uptake. We investigated the chemosensitizing potential of PPIs in colorectal cancer (CRC). Our in vitro data show that the PPI pantoprazole increases the chemosensitivity of CRC HT29 and RKO cells to fluorouracil (5-FU). Our in vivo data demonstrate that pantoprazole also increases the ability of 5-FU to inhibit CRC tumor growth in mice...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28931098/-differential-diagnosis-and-treatment-of-nausea-and-vomiting-associated-with-cancer-or-its-treatment
#2
Csaba Simkó
Nausea and vomiting are frequent and fearful issues both of cancer itself and its treatment, resulting in reduced quality of life, hospitalization and unnecessary medical investigations. Unconventionally, the author discusses the treatment-related and non-treatment-related complaints together, so as to give an integrated approach to this problem. Different types of nausea/vomiting and important causes are explained by discussion of the pathophysiology and clinical symptoms. Different classes of antiemetics are detailed, emphasizing the evolving role of olanzapine in the treatment of both the acute and delayed type of chemotherapy-induced nausea/vomiting...
September 20, 2017: Magyar Onkologia
https://www.readbyqxmd.com/read/28930222/add-on-complementary-medicine-in-cancer-care-evidence-in-literature-and-experiences-of-integration
#3
REVIEW
Elio Rossi, Mariella Di Stefano, Fabio Firenzuoli, Maria Valeria Monechi, Sonia Baccetti
Background: According to the literature an increasing number of cancer patients demand for complementary therapies during their disease. Research has demonstrated that some of these therapies are effective and safe as adjunctive treatments in specific symptoms of these patients. Methods: The aims of the paper are to review the main and recent papers of international literature on the effectiveness of complementary medicine (CM) therapies on side effects of anti-cancer protocols and improvement in the quality of life of oncological patients, and to describe the integration of evidence-based acupuncture, herbal medicine and homeopathy treatments in Public Cancer Network of the region of Tuscany...
January 24, 2017: Medicines (Basel, Switzerland)
https://www.readbyqxmd.com/read/28929404/rolapitant-a-review-in-chemotherapy-induced-nausea-and-vomiting
#4
Young-A Heo, Emma D Deeks
Oral rolapitant (Varubi™; Varuby(®)), a long-acting neurokinin-1 (NK1) receptor antagonist (RA), is indicated in the USA and EU as part of an antiemetic regimen to prevent delayed chemotherapy-induced nausea and vomiting (CINV) in adults receiving highly or moderately emetogenic chemotherapy (HEC or MEC). In randomized, phase III trials, a single oral dose of rolapitant 180 mg was effective in preventing delayed CINV compared with placebo, when each was used in combination with a 5-HT3 RA plus dexamethasone, in adults receiving their first course of HEC or MEC...
September 20, 2017: Drugs
https://www.readbyqxmd.com/read/28919769/evaluating-the-antiemetic-administration-consistency-to-prevent-chemotherapy-induced-nausea-and-vomiting-with-the-standard-guidelines-a-prospective-observational-study
#5
Afsaneh Vazin, Davood Eslami, Ebrahim Sahebi
Nausea and vomiting (NV) are the most prevalent adverse effects of chemotherapy (CT). This study was conducted to evaluate adherence of the health care team to standard guidelines for antiemetics usage to prevent acute chemotherapy-induced nausea and vomiting (CINV) in a large CT center. A prospective study was performed during an 11-month period on patients receiving CT. A form was designed to collect patients' demographic information and their chemotherapeutic and antiemetic regimen data. The Likert scale was used to measure the effectiveness of the antiemetics in patients...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28919712/recent-developments-in-the-clinical-pharmacology-of-rolapitant-subanalyses-in-specific-populations
#6
REVIEW
Bernardo Leon Rapoport, Matti Aapro, Martin R Chasen, Karin Jordan, Rudolph M Navari, Ian Schnadig, Lee Schwartzberg
Knowledge of the involvement of the neurokinin substance P in emesis has led to the development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of chemotherapy-induced nausea and vomiting (CINV), in combination with serotonin type 3 receptor antagonists and corticosteroids. The NK-1 RA rolapitant, recently approved in oral formulation, has nanomolar affinity for the NK-1 receptor, as do the other commercially available NK-1 RAs, aprepitant and netupitant. Rolapitant is rapidly absorbed and has a long half-life in comparison to aprepitant and netupitant...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28917369/emesis-in-patients-receiving-acupuncture-sham-acupuncture-or-standard-care-during-chemo-radiation-a-randomized-controlled-study
#7
Ylva Widgren, Anna Enblom
OBJECTIVE: To study nausea, vomiting and need for rescue antiemetics in patients receiving antiemetic acupuncture, sham acupuncture or standard care during concomitant chemotherapy during pelvic radiotherapy. METHODS: In total, 68 patients participated (75% women, mean age 56 years, 53% had gynecological, 43% colorectal, and 4% other cancer types). Fifty-seven of them were blinded randomized to verum (n=28) or sham (n=29) acupuncture, median 10 sessions. During the study period of four weeks, the patients daily registered their nausea, vomiting and consumption of antiemetics...
October 2017: Complementary Therapies in Medicine
https://www.readbyqxmd.com/read/28906589/neoadjuvant-therapy-of-bevacizumab-in-combination-with-oxaliplatin-and-capecitabine-xelox-for-patients-with-metastatic-colorectal-cancer-with-unresectable-liver-metastases-a-phase-ii-open-label-single-arm-noncomparative-trial
#8
Hong-Hwa Chen, Jen-Kou Lin, Joe-Bin Chen, Chieh-Han Chuang, Mei-Ching Liu, Jen-Yi Wang, Chung-Rong Changchien
AIM: This phase II, open-label study evaluated the efficacy and safety of neoadjuvant therapy with bevacizumab plus XELOX (capecitabine and oxaliplatin) for untreated metastatic colorectal cancer with unresectable liver metastases and assessed conversion of unresectable to resectable metastases after neoadjuvant treatment. METHODS: Patients received bevacizumab 5 mg/kg and oxaliplatin 85 mg/m(2) on day 1, and capecitabine 1000 mg/m(2) twice daily on days 1-5 followed by 2 days of rest in a 14-day cycle for 12 cycles; bevacizumab was excluded in cycles 6 and 7...
September 14, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28906561/bioequivalence-of-intravenous-and-oral-rolapitant-results-from-a-randomized-open-label-pivotal-study
#9
Xiaodong Wang, Zhi-Yi Zhang, Daniel Powers, Jing Wang, Sharon Lu, Sujata Arora, Lorraine Hughes, Jennifer Christensen, Vikram Kansra
Rolapitant, a selective and long-acting neurokinin-1 receptor antagonist, is approved in an oral formulation for the prevention of delayed chemotherapy-induced nausea and vomiting in adults. The objective of this pivotal study was to assess the bioequivalence of a single intravenous infusion of rolapitant versus a single oral dose of rolapitant. In this randomized, open-label phase 1 study, healthy volunteers were administered rolapitant as a 180-mg oral dose or a 30-minute 166.5-mg intravenous infusion. Blood samples for pharmacokinetic analysis were collected predose and at points up to 912 hours postdose...
September 14, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28906558/effects-of-rolapitant-administered-intravenously-or-orally-on-the-pharmacokinetics-of-digoxin-p-glycoprotein-substrate-and-sulfasalazine-breast-cancer-resistance-protein-substrate-in-healthy-volunteers
#10
Xiaodong Wang, Zhi-Yi Zhang, Sujata Arora, Lorraine Hughes, Jing Wang, Daniel Powers, Jennifer Christensen, Sharon Lu, Vikram Kansra
Rolapitant is a selective and long-acting neurokinin-1 receptor antagonist approved in an oral formulation in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting in adults. Four open-label phase 1 studies evaluated the safety and drug-drug interactions of a single dose of rolapitant given intravenously (166.5 mg) or orally (180 mg) with oral digoxin (0.5 mg) or sulfasalazine (500 mg), probe substrates for the P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), respectively...
September 14, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28900996/-clinicopathologic-characteristics-and-prognosis-of-gastric-hepatoid-adenocarcinoma
#11
Rongfei Zhao, Xinxin Wang, Xin Lan, Mingsen Li
OBJECTIVE: To investigate the clinicopathological characteristics, diagnosis, treatment and prognosis of gastric hepatoid adenocarcinoma(HAS). METHODS: Retrospective analysis of clinicopathological data of 24 cases with gastric HAS diagnosed by surgery and pathology in Chinese PLA General Hospital from January 2013 to May 2016 were carried out. All the patients underwent preoperative serum alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), endoscopy and imaging examination (CT or B-mode ultrasonography), and those with elevated AFP were excluded from liver cancer, cirrhosis, endodermal sinus tumor and other diseases...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28900321/pattern-of-adverse-drug-reactions-to-anticancer-drugs-a-quantitative-and-qualitative-analysis
#12
Shruti Singh, D C Dhasmana, Manisha Bisht, Prashant Kumar Singh
INTRODUCTION: Anticancer drugs contribute significantly to the global burden of adverse drug reactions (ADRs). Any attempt to quantify their magnitude and provide upgraded knowledge would help oncologists in writing safer prescriptions. AIM: This observational follow-up study was conducted on newly diagnosed cancer patients receiving anticancer therapy with an aim to determine the frequency, severity, causality, predictability, and preventability of ADRs. SUBJECTS AND METHODS: The patients were followed up for 6 months for the appearance of adverse events...
April 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/28891234/retrospective-analysis-of-nonradiation-complications-in-dogs-undergoing-radiation-therapy
#13
John Farrelly, Qiuhu Shi
Dogs receiving radiation can develop complications unrelated to the radiation treatment. No study to date has described these complications in clinical patients undergoing multiple radiation therapy treatments. The purpose of this retrospective case-control study was to characterize the incidence and type of complications that occur in these dogs. A secondary goal was to evaluate whether patient and treatment characteristics could be identified to predict the risk of these complications. Medical records of 268 dogs receiving at least one radiation treatment at a single institution, between September, 2004 and June, 2007 were reviewed...
September 10, 2017: Veterinary Radiology & Ultrasound
https://www.readbyqxmd.com/read/28890296/thalidomide-reduces-chemotherapy-induced-vomiting
#14
Elizabeth Gourd
No abstract text is available yet for this article.
September 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28888914/acute-diffuse-peritonitis-due-to-spontaneous-rupture-of-a-primary-gastrointestinal-stromal-tumor-of-the-jejunum-a-case-report
#15
Koki Sato, Hirofumi Tazawa, Seiji Fujisaki, Sotaro Fukuhara, Koki Imaoka, Yuzo Hirata, Mamoru Takahashi, Saburo Fukuda, Yoshio Kuga, Toshihiro Nishida, Hideto Sakimoto
INTRODUCTION: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Overt peritonitis caused by GIST rupture is very uncommon. Three types of GIST rupture have been described: closed perforation due to abscess (abscess type), hemoperitoneum leading to rupture of the hematoma capsule in the tumor (hemoperitoneum type), and perforation of the digestive tract via a fistula leading to central necrosis of the tumor (bowel perforation type)...
August 23, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28882436/antitumor-activity-and-safety-of-the-parp-inhibitor-rucaparib-in-patients-with-high-grade-ovarian-carcinoma-and-a-germline-or-somatic-brca1-or-brca2-mutation-integrated-analysis-of-data-from-study-10-and-ariel2
#16
Amit M Oza, Anna V Tinker, Ana Oaknin, Ronnie Shapira-Frommer, Iain A McNeish, Elizabeth M Swisher, Isabelle Ray-Coquard, Katherine Bell-McGuinn, Robert L Coleman, David M O'Malley, Alexandra Leary, Lee-May Chen, Diane Provencher, Ling Ma, James D Brenton, Gottfried E Konecny, Cesar M Castro, Heidi Giordano, Lara Maloney, Sandra Goble, Kevin K Lin, James Sun, Mitch Raponi, Lindsey Rolfe, Rebecca S Kristeleit
OBJECTIVE: An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcinoma (HGOC). METHODS: Eligible patients from Study 10 (NCT01482715) and ARIEL2 (NCT01891344) who received a starting dose of oral rucaparib 600mg twice daily (BID) with or without food were included in these analyses. The integrated efficacy population included patients with HGOC and a deleterious germline or somatic BRCA1 or BRCA2 (BRCA1/2) mutation who received at least two prior chemotherapies and were sensitive, resistant, or refractory to platinum-based chemotherapy...
September 4, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28881696/the-effect-of-intraperitoneal-chemotherapy-on-early-pain-hyperalgesia-in-patients-following-elective-laparoscopic-transabdominal-resection-of-rectal-cancer
#17
Min Liang, Chang-Ying Li, Chun-Guang Ren, Zong-Wang Zhang, Zhi-Jian Fu
BACKGROUND: Chemotherapy has been associated with hyperalgesia. This prospective study was designed to investigate the effect of intraperitoneal chemotherapy with lobaplatin on post-operative pain intensity and sufentanil requirements after laparoscopic transabdominal resection of rectal cancer. METHODS: Eighty subjects (40 subjects treated with intraperitoneal chemotherapy and 40 subjects without chemotherapy treatment) scheduled for laparoscopic transabdominal resection of rectal cancer were included in this study...
August 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28878613/mixed-adenocarcinoma-and-squamous-cell-carcinoma-of-duodenum-a-case-report-and-review-of-the-literature
#18
Muhammad Bader Hammami, Anuj Chhaparia, Jinhua Piao, Yihua Zhou, Christine Hachem, Jinping Lai
Despite being the largest part of the human gastrointestinal (GI) tract, the small intestine accounts for only 1-1.4% of all GI malignancies. Adenocarcinoma is the most common primary small bowel malignancy, with the most common site being the duodenum. On the other hand, squamous cell carcinoma (SCC) of the duodenum is extremely uncommon. We report the first case of mixed adenocarcinoma and SCC occurring in the third part of duodenum (D3). Our patient, a 64-year-old female with history of GERD, hypertension, and IDDM presented with 4 weeks of nausea, vomiting, and abdominal pain...
May 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/28871358/chemotherapy-induced-nausea-and-vomiting-cinv-and-adherence-to-antiemetic-guidelines-results-of-a-survey-of-oncology-nurses
#19
Rebecca Clark-Snow, Mary Lou Affronti, Cynthia N Rittenberg
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients with use of guideline-recommended antiemetic regimens. However, studies have suggested that adherence to antiemetic guidelines is suboptimal. Oncology nurses, as part of a multidisciplinary team, can help promote appropriate antiemetic prophylaxis. Therefore, nurses were surveyed to assess antiemetic guideline awareness and practice patterns of antiemetic use, determine adherence to guideline recommendations, and query barriers to adherence...
September 4, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28867732/comparison-between-antiemetic-effects-of-palonosetron-and-granisetron-on-chemotherapy-induced-nausea-and-vomiting-in-japanese-patients-treated-with-r-chop
#20
Mayako Uchida, Yasuo Mori, Tsutomu Nakamura, Koji Kato, Kenjiro Kamezaki, Katsuto Takenaka, Motoaki Shiratsuchi, Kaori Kadoyama, Toshihiro Miyamoto, Koichi Akashi
In the present study, the antiemetic effect of palonosetron, not combined with dexamethasone and aprepitant, on chemotherapy-induced nausea and vomiting was evaluated in patients with malignant lymphoma receiving first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, and was compared to that of granisetron. A total of 74 patients with non-Hodgkin lymphoma were included in this study (April 2007 to December 2015). Palonosetron (0.75 mg) or granisetron (3 mg) was intravenously administered before R-CHOP therapy...
2017: Biological & Pharmaceutical Bulletin
keyword
keyword
107786
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"